Are we underestimating urinary retention following intravesical onabotulinumtoxinA in women with overactive bladder and a history of prior pelvic surgery?-Reference-Cited by-同舟云学术

Are we underestimating urinary retention following intravesical onabotulinumtoxinA in women with overactive bladder and a history of prior pelvic surgery?

Published:2022-10-02 Issue:1 Volume:42 Page:106-112
ISSN:0733-2467
Container-title:Neurourology and Urodynamics
language:en
Short-container-title:Neurourology and Urodynamics

Author:

Holmes Angela¹^ORCID,Kelsey Ellen¹^ORCID,Wombwell Amy¹^ORCID,Molesworth Charlotte²^ORCID,McLeod Kathryn¹³^ORCID

Affiliation:

1. Department of Urological Surgery, Barwon Health University Hospital Geelong Geelong Victoria Australia

2. Department of Biostatistics Deakin University Geelong Victoria Australia

3. Department of Surgery, School of Medicine Deakin University Geelong Victoria Australia

Publisher

Wiley

Subject

Urology,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/nau.25054

Reference11 articles.

1. Fourth international consultation on incontinence recommendations of the international scientific committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence

2. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

3. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study

4. OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

5. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial